India Ink: Forces of Creation Moving in Unison





Presenting non-Western dances to Western audiences can be a difficult business. If an artist adjusts too much, a deep tradition can flatten into pandering tourist fare. If an artist adjusts too little, fidelity can get in the way of communication; a living art form can come across as a relic.







Andrea Mohin/The New York Times

Bijayini Satpathy, left, and Pavithra Reddy of the Nrityagram Dance Ensemble in “Alap.”












A sortable calendar of noteworthy cultural events in the New York region, selected by Times critics.





The Indian choreographer Surupa Sen negotiates the balance with grace. The sinuous, asymmetrical poses of her Odissi tradition, looking at once immovable and full of motion, disguise complex negotiations with gravity as mere embellishments of line. Similarly, Ms. Sen’s choreography elaborates on classical Odissi style while seeming merely to clarify it.


For 20 years Ms. Sen has worked closely with the dancer Bijayini Satpathy. For 20 years, in fact, the two women have lived in the same village in Southern India, Nrityagram, which is devoted to dance. The concert of duets and solos they’re bringing to the Skirball Center (April 6 to 7) is titled “Samyoga,” which in Sanskrit means “union” or “the conjunction of heavenly bodies.” That’s a fair description of Ms. Sen and Ms. Satpathy dancing together.


There’s a philosophical idea behind the work — the interaction between male and female principles in creation — but it can be appreciated on purely aesthetic and theatrical grounds. The women dance both male and female roles. Suggestions of demons and giant birds blend into abstract shapes, patterns and rhythms. A love spat between gods is presented as human comedy, in motion touched by the divine. And, as at all events presented by the World Music Institute, the live music should be at least as distinguished as the dancing.


Souleymane Badolo takes on the translation challenge from a different angle. Born in Burkina Faso, he started his dancing career there, in a traditional African troupe. Since 1993 he has been experimenting with Western contemporary dance, performing in Africa and Europe, but the first work he presented in New York, after he moved there in 2009, still looked pretty foreign. Telling his story in a mixture of French and his native language, Gurunsi, Mr. Badolo enacted a private ritual, slapping his flesh and clicking his tongue.


Since then it’s been fascinating to watch him adapt to his new home. Working with Reggie Wilson, a New York postmodern choreographer well versed in African dance, Mr. Badolo has become more postmodern and more New York. For his performances at New York Live Arts (April 25 to 27) he’s looking again at legacy, the line from his great-great-grandfather to his son. He’s also creating a piece based on a Gurunsi divination method involving the scattering of cowrie seeds.


Is that so different from Merce Cunningham’s chance practices? Is there such a great distance between Africa and downtown New York?


Read More..

Jennifer Lawrence Falls - But Shakes It Off - and Wins Best Actress









02/25/2013 at 12:50 AM EST







Jennifer Lawrence accepts the Best Actress Oscar


Kevin Winter/Getty


It was perhaps the most unpredictable moment of the Oscars Sunday night when Jennifer Lawrence made her way to the stage to accept her Oscar for Best Actress for her role in Silver Linings Playbook on Sunday.

The 22-year-old actress slipped on the stairs but luckily her full skirted Dior Haute Couture gown cushioned her fall.

After she slipped, gentleman Hugh Jackman was spotted rushing to aid if necessary. "I had to help her, poor thing! I didn't know if she could get up," he told PEOPLE after the show.

Lawrence was unfazed: "Thank you!" she began as she stood at the podium clutching her award. "You guys are just standing up 'cause you feel bad that I fell and that's really embarrassing, but thank you."

She continued: "This is nuts! Thank you to the Academy and thank you to the women this year, you were so magnificent. You were so inspiring and not just those of you in my category; and it's been so amazing getting to know you and you've been so nice and you've made this experience unforgettable."

While thanking her team, family and fellow cast members, Lawrence even managed to sneak in a birthday shootout to French actress (and fellow Best Actress nominee) Emmanuelle Riva who turned 86 on Sunday.

But after the awards show had ended, Lawrence remained in good spirits about her slip. Backstage in the press room, she joked first that she had done it on purpose and then quipped that someone had "waxed the stairs."

It's been a whirlwind awards season for Lawrence who also won a Screen Actors Guild Award and Golden Globe.

– With Reporting by Julie Jordan and Elizabeth Leonard

Jennifer Lawrence Falls – But Shakes It Off – and Wins Best Actress| Academy Awards, Oscars 2013, Jennifer Lawrence

Lawrence in Dior

Kevin Winter / Getty

Read More..

FDA approves new targeted breast cancer drug


WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.


The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.


Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.


"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."


Cobleigh helped conduct the key studies of the drug at the Chicago facility.


The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.


The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.


Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.


FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.


Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.


FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer


Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.


Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.


Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.


Read More..

Mahony answers questions under oath about clergy sex abuse cases









A "relatively unflappable" Cardinal Roger Mahony answered questions under oath for more than 3 1/2 hours Saturday about his handling of clergy sex abuse cases, according to the lawyer who questioned the former archbishop.


"He remained calm and seemingly collected at all times," said attorney Anthony De Marco, who represents a man suing the Los Angeles Archdiocese over abuse he alleges he suffered at the hands of a priest who visited his parish in 1987.


Mahony has been deposed many times in the past, but Saturday's session was the first time he had been asked about recently released internal church records that show he shielded abusers from law enforcement.





De Marco declined to detail the questions he asked or the answers the cardinal provided, citing a judge's protective order.


The deposition occurred just before Mahony was to board a plane for Italy to vote in the conclave that will elect the next pope. In a Twitter post Friday, Mahony wrote that it was "just a few short hours before my departure for Rome."


Church officials did not return requests for comment.


The case, set for trial in April, concerns a Mexican priest, Nicholas Aguilar Rivera. Authorities believe he molested at least 26 children during a nine-month stay in Los Angeles.


Recently released church files show Aguilar Rivera fled to Mexico after a top Mahony aide, Thomas Curry, warned him that parents were likely to go the police and that he was in "a good deal of danger." Aguilar Rivera remains a fugitive in Mexico.


The archdiocese had agreed that Mahony could be questioned for four hours about the Aguilar Rivera case and 25 other priests accused in the same period. De Marco said he did not get to ask everything he wanted and would seek additional time after the cardinal returned from the Vatican.


Past depositions of Mahony have eventually become public, and De Marco said he would follow court procedures to seek the release of a transcript of Saturday's deposition.


Meanwhile, a Catholic organization Saturday delivered a petition with thousands of signatures asking that Mahony recuse himself from the conclave in Rome.


The group, Catholics United, collected nearly 10,000 signatures making "a simple request" that the former archbishop of Los Angeles not participate in the process because of the priest abuse scandals that happened under his watch, said Chris Pumpelly, communications director for Catholics United.


The petition was delivered Saturday to St. Charles Borromeo in North Hollywood, where the cardinal resides. It was accepted by a church staff member.


After delivering the petition, organizers attended Mass at the parish to pray for healing and for the future of the church.


harriet.ryan@latimes.com


Times staff writer Rick Rojas contributed to this report.





Read More..

2 Palestinians Shot in Clashes With Israeli Settlers





JERUSALEM (AP) — Clashes erupted Saturday in the West Bank, with Jewish settlers shooting two Palestinian demonstrators in the northern village of Kusra, an Israeli military official and Palestinian residents said.




The unrest reflected mounting friction in the West Bank, where Palestinians have faced off against Israeli troops in recent weeks in a series of large demonstrations protesting Israel’s control of the territory in general and in solidarity with four prisoners on hunger strikes in Israeli jails.


Also on Saturday, a Palestinian prisoner died in an Israeli jail, an event that is likely to intensify tensions in the area.


In the West Bank skirmish, Helmi Abdul-Aziz, 24, was shot in the stomach by Jewish settlers, Palestinian demonstrators said. They said settlers also shot Mustafa Hilal, 14, in the foot.


An Israeli military official confirmed that two Palestinians had been shot, apparently by settlers, since the Israeli military forces there were not using live ammunition.


Villagers said the clashes began when a group of Jewish settlers encroached on their village lands and fired guns. They said settlers chased a Palestinian farmer and his family off land, prompting the farmer to call on other villagers to confront the settlers, and men on both sides hurled rocks at one another.


In an Israeli jail on Saturday, Arafat Shalish Shahin Jaradat, a Palestinian prisoner, died apparently of a heart attack, according to an Israeli prison services spokeswoman, Sivan Weizman. She said that Mr. Jaradat had not been on a hunger strike.


Israel’s domestic intelligence agency, the Shin Bet, said that Mr. Jaradat, 30, was arrested last week after he was involved in a rock-throwing attack that injured an Israeli citizen. Mr. Jaradat admitted to the charge, as well to another West Bank rock-throwing episode last year, the Shin Bet said.


A Shin Bet spokesman said that Mr. Jaradat had not been beaten during an interrogation.


Read More..

Breaking Dawn - Part 2 Sweeps the Razzies









02/23/2013 at 10:00 PM EST







Taylor Lautner and Mackenzie Foy, in Breaking Dawn – Part 2


Andrew Cooper, SMPSP/Summit


Who's misérable now?

The Twilight Saga: Breaking Dawn – Part 2, Adam Sandler and Rihanna are among the "winners" of the 33rd annual Golden Raspberry Awards – the Razzies – which are not so much handed out as they are thrown at those who are voted as perpetrating Hollywood's worst achievements of the year.

Breaking Dawn – Part 2, the fifth and final installment in Stephenie Meyer's vampire saga, was recognized in seven categories, including worst picture.

The flick's Kristen Stewart was also cited as worst actress; Taylor Lautner, worst supporting actor; Lautner and 12-year-old Mackenzie Foy, worst screen couple; the entire cast, including Robert Pattinson, worst screen ensemble, and Bill Condon, worst director.

In addition, the film, which since opening last November has taken in more than $828 million at the box office, was named worst sequel.

Sandler, who last year monopolized the Razzies – and set a record by winning in 10 categories with the "comedy" Jack & Jill – this year got only two awards: for worst actor of the year and worst screenplay, both for That's My Boy.

Unlike the Oscars, which keep voting tallies a secret and will be handed out Sunday night during a very glamorous event, founder and Head RAZZberry John Wilson announced Razzie recipients Saturday night in the utilitarian Continental Breakfast Room of the Holiday Inn Express Hollywood Walk of Fame hotel, near (and yet so far from) the Dolby Theatre, home of the Academy Awards.

Wilson revealed to the press that although Rihanna, as worst supporting actress in the movie Battleship, won her Razzie by a landslide, worst screenwriter Sandler only beat the authors of Breaking Dawn by a single vote.

It's close shaves like that that really make or break the Razzies.

Breaking Dawn – Part 2 Sweeps the Razzies| Oscars 2013, The Razzies 2013, Movies, Battleship, That's My Boy, News Franchises, Individual Class, Adam Sandler, Kristen Stewart, Rihanna, Robert Pattinson

Adam Sandler, in That's My Boy, and Rihanna, in Battleship

Columbia; Universal

The 85th annual Academy Awards will air live on ABC starting at 7 p.m. ET/4 p.m. PT on Sunday, Feb. 24, from the Dolby Theatre in Hollywood.
Read More..

FDA approves new targeted breast cancer drug


WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.


The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.


Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.


"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."


Cobleigh helped conduct the key studies of the drug at the Chicago facility.


The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.


The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.


Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.


FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.


Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.


FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer


Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.


Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.


Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.


Read More..

Oyster farm fight has many interested parties









POINT REYES NATIONAL SEASHORE — To hear Kevin Lunny tell it, he's just a little guy, draining his life's savings to stand up to a heartless federal agency bent on closing down his family's oyster farm here.


It's a compelling tale, a years-long soap opera replete with allegations of scientific misconduct and government overreach. Tea party activists have taken up his cause, citing it as an example of government quashing free enterprise and environmentalism run amok. Lunny also has the support of powerhouse conservative law firms representing him pro bono, and Cause of Action, a Washington, D.C.-based government watchdog group with ties to the conservative Koch brothers.


Others, however, don't buy his story. They say Lunny and some of his supporters have distorted what is a very simple case: The owners of the oyster farm north of San Francisco agreed 40 years ago to shut down in 2012, and Lunny is trying to break the contract.





"This thing has been hijacked by people with different agendas and manufactured narratives," said Tom Strickland, former assistant secretary of the Interior. "When someone suggests that this is 'the government versus the little guy,' I think the question should be looked at in reverse. Who is looking out for the interest of individual Americans, who is looking out for the interests of taxpayers?"


In 2005, the Lunny family bought the oyster farm in Drakes Estero, which includes the tidal area where explorer Sir Francis Drake is believed to have made landfall 430 years ago. With the purchase, the family signed on to an existing 40-year agreement with the National Park Service stating that the business would cease operations last fall and the area would convert to marine wilderness, as Congress intended.


From the beginning, Lunny made clear to the Park Service that he was interested in staying on, but Interior's solicitor ruled the agency had no legal basis to allow that.


The often-ugly debate reached a crescendo three months ago when Interior Secretary Ken Salazar elected not to extend Lunny's permit to operate in Point Reyes National Seashore. The operation is scheduled to be removed next month, clearing the way for Drakes Estero, a dramatic coastal sweep of five bays in Marin County, to become the first marine wilderness in the Lower 48 states.


Lunny filed a lawsuit to force the government to extend his lease, but it failed in federal court. He said he is appealing to the 9th Circuit Court of Appeals in San Francisco.


"To my mind, the issue really centers on the original deal," said Lynn Scarlett, an assistant secretary of the Interior under George W. Bush. "When this area was designated as a national park unit, the Congress and all those who were engaged struck a deal. A deal's a deal."


Lunny casts the debate in different terms. He says that the government is being unfair and that his protracted fight to stay has devastated his family. U.S. Sen. Dianne Feinstein (D-Calif.), who wrote two bills to help Lunny continue operating in the park, wrote Salazar to say that because of the oyster farm's impending closure, Lunny's family is "facing financial ruin."


The family does have other sources of income. They run a cattle ranch on federal land and own a paving and construction business. Lunny's legal fight is being waged by lawyers working for free, five of whom joined him at his last court appearance. He is soliciting online donations via the Farm-to-Consumer Legal Defense Fund and has a shellfish industry lobbyist on his payroll as a consultant.


Records obtained under the Freedom of Information Act show that the federal government has extended generous subsidies to the Lunny family for decades. The extended family has leased more than 1,100 acres, where it raises cattle within the park. The grazing rate Lunny and other ranchers pay is about one-third the amount ranchers are charged on adjacent private land.


The Lunnys' lease includes a three-bedroom house, a second residence and a bunkhouse, all owned by the federal government but leased by the family. Lunny pays $2,200 a month for the 1,100 acres and the buildings — about what renters nearby pay to lease a single-family house on a small plot of private land.


The Park Service, under political pressure to help Lunny, recently spent $50,000 to replace the roofs on two of the family's leased buildings. Other federal seashore tenants are required to pay for their own home maintenance.


The Park Service, however, has made mistakes in the case that have given ammunition to the Lunnys' supporters. In 2007, a seashore scientist wrote a flawed report that suggested Lunny's farm harmed harbor seals.


The Park Service acknowledged the errors and retracted the study, but the episode gave credibility to claims that the park was using "junk science" to force Lunny out.


At Feinstein's urging, the Park Service commissioned outside reviews of its ongoing study of Drakes Estero. The effort to resolve the scientific debate has morphed into a multimillion-dollar morass of scientific studies and investigations by Interior's inspector general, the National Academy of Sciences and the Marine Mammal Commission, paid for by taxpayers.


The results: In some instances the Park Service conclusions overreached, in some instances they were correct, and most of the time it was impossible to determine the accuracy of any claim without more study.


Apart from his trouble with the park, Lunny has a history of not complying with California Coastal Commission orders. For six years, Lunny's farm has failed to acquire the appropriate state permits to operate in a coastal zone.


The Coastal Commission earlier this month issued its second cease-and-desist order to the farm. "I find that this is one of the most egregious, egregious violations that I have seen," Commissioner Esther Sanchez said in a hearing.


Now that Drakes Bay Oyster Co.'s closure looms, the farm's plight has become a cause for groups with disparate agendas. Some represent the interests of the shellfish industry, which seeks to operate in protected waters up and down the coast. Some favor more commercial activities in national parks, and others espouse virulently anti-government views.


Lunny's supporters are threatening to stage protests and even blockade the road if authorities are required to escort Lunny and his staff from the seashore.


Lunny, a genial and quiet man, said he doesn't want to be associated with "right-wing land rights and anti-government groups."


"This has spun out of control like none of us would ever have imagined," Lunny said. "Some of these groups came out of the woodwork" after Salazar decided against extending the lease. "All of a sudden we have some new friends."


julie.cart@latimes.com





Read More..

IHT Rendezvous: IHT Quick Read: Feb. 23

NEWS Since the days of the Medici family in Florence, the banking house of Monte dei Paschi has rained wealth on the people of Siena, Italy. For 541 years, it has endured war, plague and panic, and it stands today as the world’s oldest operating bank. But inside the stately offices of Monte dei Paschi di Siena, a thoroughly modern fiasco has done what the centuries could not. Monte dei Paschi, founded in 1472, has been brought to its knees by 21st-century finance. Jack Ewing and Gaia Pianigiani report from Siena.

Despite growing confidence that Europe is managing its debt crisis and is poised to embark on a recovery, fresh developments on Friday indicated that the region continues to struggle to stimulate growth while cutting spending to pare deficits. James Kanter reports from Brussels.

Alcatel-Lucent, the struggling French telecommunications equipment maker, on Friday hired a former Vodafone and France Télécom executive, Michel Combes, to lead the company through what might be a major downsizing. Mr. Combes, 51, will take over for Ben Verwaayen, who had failed in four years to bring the equipment maker, created by the 2006 merger of Alcatel of France and Lucent Technologies of New Jersey, to sustained profit. Kevin J. O’Brien reports from Berlin.

Another big food producer was ensnared in the scandal over horse meat in beef products Friday when the company that owns the Iglo and Birds Eye brands withdrew a dozen types of prepared meals from stores in four European countries. The Iglo Foods Group, the parent company, said it took the action after a chili con carne dish, produced by a Belgian company called Frigilunch and on sale in Belgium, was found to contain about 2 percent horse meat. Stephen Castle reports from London.

A deadly attack by militants on an Algerian natural gas plant last month has dealt a major setback to a group of North African countries whose prospects as oil and gas producers were already cloudy. Both oil and natural gas production have been in decline in Algeria, the region’s biggest gas producer, since the mid-2000s. In Libya, the rebellion that ousted Col. Muammar el-Qaddafi and its chaotic aftermath have disrupted oil and gas exploration. In Egypt, rising domestic consumption, encouraged by government policies, has cut into exports. Stanley Reed reports from London.

ARTS The director David Lynch has released a musical album, exhibited his artwork, designed a nightclub and worked tirelessly for T.M. What he has not been doing is making movies. Claire Hoffman reports from Los Angeles.

Read More..

Courtney Lopez: Gia Thinks Our Dog Is Having a Baby




Celebrity Baby Blog





02/22/2013 at 01:00 PM ET



Courtney Lopez: Gia Thinks Dog Having Baby
Denise Truscello/Wireimage


Mario Lopez is a man of his word.


Following a December wedding, the EXTRA host declared he and wife Courtney would get to work expanding their family immediately — and he wasn’t kidding.


In January, the couple discovered they were indeed expecting.


“Mario and I are so excited to add to our family! I found out a month ago and surprised Mario with the good news at breakfast,” Courtney tells PEOPLE.


But the proud parents aren’t the only ones gearing up for a new addition. Big sister Gia Francesca, 2, already has babies on the brain.


“Gia kind of understands that there is a baby in my belly,” Courtney notes. “She also told me our dog Julio has a baby in his belly — so who knows!”

Despite a bumpy start — “I had a rough couple of weeks when I first found out,” she shares — the mom-to-be is feeling better and already sporting quite the blossoming belly. “I am showing so much faster this time around,” she says.


And with warmer weather on the way, Courtney will be swathing her bump in floor-length frocks — but plans on forgoing a few fashion ensembles from her past.


“I love being pregnant in the summer! I live in maxi dresses,” she says. “Looking back at my first pregnancy, there are certain things that I wore and I have no idea why. I looked horrible and I won’t do that again!”


Originally from Pittsburgh, the expectant mama is thrilled to have settled down with her growing family on the West Coast. Her only wish? That her children will one day enjoy a winter wonderland.


“I don’t miss the East Coast at all — especially the humidity,” she explains. “The one thing I do want my children to experience from an early age is snow. There is nothing like being a kid playing in the snow.”


– Anya Leon


Read More..